Domestic Bio Companies Target Animal Pharmaceutical Market with Innovative Treatments

Domestic bio companies are making significant strides in the animal pharmaceutical market, conducting research and development on a range of topics, from skin diseases to anticancer treatments and cognitive dysfunction syndrome.

CTC Bio Expands into Pet Market with Natural Bathing Agent

CTC Bio, a pharmaceutical research and development company, has launched ‘Ecosin’, a foaming natural bathing agent for pets, as the first new product from its pet business division. Ecosin is a product researched and developed by Czech company Bad, and is effective in cleaning the skin and fur of animals caused by bacterial skin diseases, fungal skin diseases, seborrheic inflammation, and wounds.

CTC Bio has been increasing its competitiveness in the domestic and international livestock markets, with its ‘CTCzyme’ digestive enzyme for feed being the first in Asia and the second in the world. The company has also signed a supply contract with global animal pharmaceutical company ‘Hubepharma’ and is pursuing cooperation with the world’s largest grain company ‘Cargill’.

Paxcell Bio Develops Anticancer Immune Therapy for Companion Dogs

Paxcell Bio, a company specializing in the development of anticancer immune cell therapy, has obtained product approval for mass production and administration dosage/methodology of ‘Baxrukin-15’ from the Animal and Plant Quarantine Agency. The company plans to actively pursue plans to export ‘Baxrukin-15’ to the US, Europe, Asia, and other countries.

‘Baxrukin-15’ has a mechanism of action that activates canine immune cells and suppresses cancer in companion dogs that is difficult to treat with existing treatments.

Domestic Pharmaceutical and Bio Companies Focus on Clinical Research

Domestic pharmaceutical and bio companies are focusing on clinical research to use human treatments as veterinary medicines. HK inno.N is developing a topical atopic dermatitis treatment based on the Janus kinase (JAK) inhibitor series, and has completed patient recruitment for a phase 1 clinical trial.

GNT Pharma, a new drug development company, has received approval from the National Institute of Animal Quarantine for an investigational new drug (IND) for canine epilepsy for its commercially available drug for canine cognitive dysfunction syndrome, Zedacure.

HLB Life Science is conducting phase 3 animal clinical trials for ‘Riboceranib’, a companion dog mammary cancer treatment. The company is also continuing research on other indications, including mammary cancer, animal lymphoma, and mast cell cancer.

Market Growth and Expansion

The domestic pet-related market has shown tremendous growth and is continuing to expand, with the pet medicine business expected to be a growth engine not only for the domestic pet business market but also for entering overseas markets.

According to global market research firm Global Information, the pet cancer treatment market size alone is expected to grow from $444.1 million in 2024 to $649.82 million by 2029, with a market growth rate of 7.91% from 2024 to 2029.